Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapy for a variety of malignancies, including leukemias, lymphomas, and myeloma. Several complications limit its use including relapse of malignancy, graft versus host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation – all of which can lead to increased morbidity and mortality after allo-HSCT. My laboratory uses murine HSCT models to study clinically important problems in HSCT and to test novel therapeutic strategies which can be translated into clinical practice.
Marcel R. M. van den Brink, MD, PhD
Research FocusPhysician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation.
- MD, PhD, Universiteit Leiden
- Velardi E, Tsai JJ, Holland AM, Wertheimer T, Yu VW, Zakrzewski JL, Tuckett AZ, Singer NV, West ML, Smith OM, Young LF, Kreines FM, Levy ER, Boyd RL, Scadden DT, Dudakov JA, van den Brink MRM. Sex steroid blockade enhances thymopoiesis by modulating Notch signaling. The Journal of Experimental Medicine . 2014 Nov 17;211(12):2341-9. doi: 10.1084/jem.20131289. Epub 2014 Oct 20.
- Hubbard-Lucey VM, Shono Y, Maurer K, West ML, Singer NV, Ziegler CG, Lezcano C, Motta AC, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MRM, Cadwell K. Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells. Immunity. 2014 Oct 16;41(4):579-91. doi: 10.1016/j.immuni.2014.09.011. Epub 2014 Oct 9. [PMID: 25308334]